This study aimed to investigate the association between sodium-glucose cotransporter-2 (SGLT-2) inhibitor use and the risk of all-cause mortality among patients with heart failure with reduced ejection fraction. The study included 6,776 patients who started SGLT-2 inhibitors and 14,686 patients who remained on standard-of-care heart failure drugs. The results showed a 25% lower risk of all-cause mortality in patients using SGLT-2 inhibitors. Additionally, SGLT-2 inhibitors were associated with a lower risk of cardiovascular mortality but not of hospital admission due to heart failure. This study supports the effectiveness of SGLT-2 inhibitors in routine clinical practice for reducing mortality in patients with heart failure with reduced ejection fraction.
Source link
SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study
